BioSpace News Archive

If approved, BHV-0223 would become the only formulation of riluzole that does not require swallowing tablets or liquids, offering an important delivery alternative for the standard-of-care treatment of ALS

Technavio analysts forecast the global probiotic drinks market to grow at a CAGR close to 7% during the forecast period, according to their latest market research report.

Fusion Antibodies plc and Analytics Engine have announced a strategic collaboration to incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx™ humanization platform.

Young football players may experience a disruption in brain development after a single season of the sport, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA).

LabFinder.com, a convenient online platform for patients to schedule their laboratory and radiology tests and access test results, has announced the addition of the GlycoMark® test to its growing subscriber network.

Vir Biotechnology Inc. andAlnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.

Acceleron Pharma Inc. today announced that senior management will participate in two upcoming healthcare investor conferences.

Vitamin and mineral supplements may be beneficial for people who aren’t getting the micronutrients they need through their diet, but do not help in preventing chronic disease, according to an updated position paper published by the Academy of Nutrition and Dietetics.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.

MicuRx Pharmaceuticals, Inc., today announced that the first patient has been enrolled in a Phase 2 clinical trial of contezolid acefosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE